September 28, 2015 (Shareholders Foundation) - An investigation on behalf of investors of Amicus Therapeutics, Inc. (NASDAQ:FOLD) shares over potential securities laws violations by Amicus Therapeutics and certain of its directors and officers in connection certain financial statements was announced.

The investigation by a law firm focuses on possible claims on behalf of purchasers of the securities of Amicus Therapeutics, Inc. (NASDAQ:FOLD) concerning whether certain statements by Amicus Therapeutics regarding its business, its prospects and its operations were materially false and misleading at the time they were made.

Shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD) grew from $1.84 per share in April 2014 to as high $18.40 per share on September 14, 2015.

On October 2, 2015, Amicus Therapeutics, Inc announced that after meeting with FDA officials earlier in the week, the company does not anticipate being in a position to submit a new drug application (NDA) for migalastat, the company's Fabry disease treatment, by the end of the year. The FDA has requested further integration of existing clinical data across studies, which will require more time to complete.
Shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD) declined from $13.75 per share on October 1, 2015 to as low as $5.69 per share on October 2, 2015.